Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells
Volume 11, Issue 17
Purchase or Subscribe
September 1, 2012
Pages 3219 - 3226http://dx.doi.org/10.4161/cc.21565
: BMI1, acute myeloid leukemia, dacinostat, deacetylase inhibitor, leukemic stem cells, self-renewal, short-term repopulation, vorinostat
Authors: Annette Romanski, Kerstin Schwarz, Maren Keller, Sarah Wietbrauk, Anja Vogel, Jessica Roos, Claudia Oancea, Boris Brill, Oliver H. Krämer, Hubert Serve, Martin Ruthardt and Gesine Bug View affiliations
Acute myeloid leukemia (AML) is a highly malignant disease that is not curable in the majority of patients. Numerous non-random genetic abnormalities are known, among which several translocations such as PLZF/RARα or AML1/ETO are known to aberrantly recruit histone deacetylases. Deacetylase inhibitors (DACi) are promising drugs leading to growth inhibition, cell cycle arrest, premature senescence and apoptosis in malignant cells. It is believed that DACi may have clinical efficacy by eradicating the most primitive population of leukemic stem and progenitor cells, possibly by interfering with self-renewal.
The aim of the study was to investigate the effects of DACi on leukemic stem and progenitor cells using murine transduction-transplantation models of hematopoietic cells harboring the leukemia-associated fusion proteins (LAFP) PLZF/RARα or a truncated AML1/ETO protein (AML1/ETO exon 9). We show that the self-renewal and short-term repopulation capacity of AML1/ETO- or PLZF/RARα-expressing Sca1+/lin- stem and progenitor cells are profoundly inhibited by clinically applicable concentrations of the DACi dacinostat and vorinostat. To further investigate the mechanisms underlying these effects, we examined the impact of DACi on the transcription factor c-MYC and the Polycomb group protein BMI1, which are induced by LAFP and involved in leukemic transformation. In AML1/ETO or PLZF/RARα-positive 32D cells, DACi-mediated antiproliferative effects were associated with downregulation of BMI1 and c-MYC protein levels. Similar effects were demonstrated in primary samples of cytogenetically defined high-risk AML patients. In conclusion, DACi may be effective as maintenance therapy by negatively interfering with signaling pathways that control survival and proliferation of leukemic stem and progenitor cells.
Received: February 21, 2012; Accepted: July 20, 2012; Published Online: August 16, 2012
Full Text - Ahead of Print Available - Log in!